Tumour Registry Breast Cancer (TMK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01351584|
Recruitment Status : Active, not recruiting
First Posted : May 11, 2011
Last Update Posted : August 25, 2017
|Condition or disease|
The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the multiple patient-reported outcomes (MaLife).
|Study Type :||Observational|
|Estimated Enrollment :||4500 participants|
|Official Title:||Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany|
|Study Start Date :||February 2007|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||December 2020|
- Course of Antineoplastic Treatment [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01351584
|Study Chair:||Hans Tesch, MD|